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Abstract
Background: To assess and compare the effectiveness and costs of Phototest, Mini Mental State Examination
(MMSE), and Memory Impairment Screen (MIS) to screen for dementia (DEM) and cognitive impairment (CI).
Methods: A phase III study was conducted over one year in consecutive patients with suspicion of CI or DEM at
four Primary Care (PC) centers. After undergoing all screening tests at the PC center, participants were extensively
evaluated by researchers blinded to screening test results in a Cognitive-Behavioral Neurology Unit (CBNU). The
gold standard diagnosis was established by consensus of expert neurologists. Effectiveness was assessed by the
proportion of correct diagnoses (diagnostic accuracy [DA]) and by the kappa index of concordance between test
results and gold standard diagnoses. Costs were based on public prices and hospital accounts.
Results: The study included 140 subjects (48 with DEM, 37 with CI without DEM, and 55 without CI). The MIS
could not be applied to 23 illiterate subjects (16.4%). For DEM, the maximum effectiveness of the MMSE was
obtained with different cutoff points as a function of educational level [k = 0.31 (95% Confidence interval [95%CI],
0.19-0.43), DA = 0.60 (95%CI, 0.52-0.68)], and that of the MIS with a cutoff of 3/4 [k = 0.63 (95%CI, 0.48-0.78), DA =
0.83 (95%CI, 0.80-0.92)]. Effectiveness of the Phototest [k = 0.71 (95%CI, 0.59-0.83), DA = 0.87 (95%CI, 0.80-0.92)] was
similar to that of the MIS and higher than that of the MMSE. Costs were higher with MMSE (275.9 ± 193.3€ [mean
± sd euros]) than with Phototest (208.2 ± 196.8€) or MIS (201.3 ± 193.4€), whose costs did not significantly differ.
For CI, the effectiveness did not significantly differ between MIS [k = 0.59 (95%CI, 0.45-0.74), DA = 0.79 (95%CI,
0.64-0.97)] and Phototest [k = 0.58 (95%CI, 0.45-0.74), DA = 0.78 (95%CI, 0.64-0.95)] and was lowest for the MMSE
[k = 0.27 (95%CI, 0.09-0.45), DA = 0.69 (95%CI, 0.56-0.84)]. Costs were higher for MMSE (393.4 ± 121.8€) than for
Phototest (287.0 ± 197.4€) or MIS (300.1 ± 165.6€), whose costs did not significantly differ.
Conclusion: MMSE is not an effective instrument in our setting. For both DEM and CI, the Phototest and MIS are
more effective and less costly, with no difference between them. However, MIS could not be applied to the
appreciable percentage of our population who were illiterate.
Background
There is currently no evidence to support screening for
cognitive impairment (CI) or dementia (DEM) in asympto-
matic subjects. However, most clinical practice guidelines
recommend maintaining an alert attitude and using
screening tests in suspected cases for the early identifica-
tion of these patients in primary care (PC) [1-3].
Short cognitive tests are considered more appropriate
screening instruments for CI and DEM [4]. The Mini
Mental State Examination (MMSE) [5] is the most widely
used but has various drawbacks [4,5], being long and com-
plex and requiring the ability to read and perform tasks
with paper and pencil. Other shortcomings include: non-
normal distribution of results, ceiling effect, high influence
of socio-educational variables, and modest reliability [6]
and validity, especially for CI [7]. These limitations have
greater impact in populations with a low educational level,
for which its use has been contraindicated by many
authors [8,9]. The absence of a standardized version is an
additional problem in Spain, where there are multiple
versions that differ in words to be recalled, sentences to be
repeated, drawings to be copied, and the order of items
* Correspondence: ccarnero@neurocenter.es
1Cognitive Behavioral Neurology Unit, Service of Neurology, Virgen de las
Nieves University Hospital, Carretera de Jaen s/n, 18013 - Granada, Spain
Full list of author information is available at the end of the article
Carnero-Pardo et al. BMC Neurology 2011, 11:92
http://www.biomedcentral.com/1471-2377/11/92
© 2011 Carnero-Pardo et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
[10]. The lack of consensus on cutoff points led some
authors [11] to recommend different cutoff scores as a
function of literacy and educational level (17/18 for illiter-
ates, 20/21 for individuals without completed primary
schooling; 23/24 for individuals with primary schooling or
higher), while the NORMACODEM group [12] proposed
applying a single cutoff value of 24/25 points and correct-
ing the score according to age and educational level.
A further limitation of the MMSE in our setting is that it
has not been studied in Spain for CI. Despite these draw-
backs, MMSE remains the most widely accepted reference
test and has even been used to regulate treatment with
anticholinesterases.
Various instruments have been developed to overcome
the limitations of the MMSE, reducing the complexity,
application time, and influence of socio-educational vari-
ables and improving the performance for CI. Instruments
recommended for use in PC [5,13,14] include the General
Practitioner Assessment of Cognition (GPCOG) [15],
Mini-Cog [16], and Memory Impairment Screen (MIS)
[17]. Mini-Cog and GPCOG have not been validated in
Spain and are not suitable for use in people with a low
educational level because they require the use of paper
and pencil. There have been three studies in Spain on the
MIS [18-20], which evaluates free recall of 4-word and
recall facilitated by semantic cues and includes a distract-
ing task during the 2-minute interval between reading and
recall. The MIS requires the ability to read and cannot be
applied to illiterates. All three Spanish studies were con-
ducted in hospital populations, except for a wide conveni-
ence sample of volunteers that served as controls in one
study [20]. There was no consensus on cutoff values, with
the first two studies recommending a cutoff score of 4/5
for DEM [19,20] but the third recommending 3/4 for
DEM and 4/5 for CI [18].
The Phototest (Additional File 1, http://www.fototest.
es) [21,22] is a very simple and short instrument (< 3
minutes) that can be applied to illiterates and assesses
multiple cognitive fields (language, executive function,
episodic memory). It comprises three parts: a naming
task with six color photographs of common objects in
prototypic position (Figure 1); a verbal fluency test
(names of people) demonstrated to be uninfluenced by
educational level [23], and, finally, free recall and recall
facilitated by cues using the 6 objects in the naming test.
There are 2 parallel versions of the test. Version A is
usually applied in Spain, but version B (Additional File 2)
is more suitable in English-speaking countries because
the first two objects in version A are virtually homopho-
nous in English (cards, car). Phototest results are nor-
mally distributed and are not influenced by educational
level [24]. It has shown good test-retest and interobserver
reliability [24], and various studies have reported that
cutoff scores of 26/27 and 28/29 points give adequate
discriminative validity for DEM and CI, respectively
[22,25,26].
The objective of this study was to assess the effective-
ness and associated costs of utilizing the Phototest,




Phase III study of diagnostic test assessment [27] with a
paired design (all screening tests were applied to all sub-
jects), with complete verification (all subjects underwent
the standard diagnostic procedure) [28].
Setting
Four PC centers in the Metropolitan District of North
Granada Area (Southern Spain).
Study population
Consecutive patients attended in PC from February 1
2008 to January 31 2009 who aroused suspicion of CI or
DEM.
Inclusion criteria
Inclusion criteria were: suspicion of CI or DEM, based
on subjective complaints of memory loss or cognitive
alteration, similar complaints made by a relative or
informer, or observation by physicians of suspicious
signs or symptoms. Exclusion criteria were previous
enrolment in this study or previous diagnosis of CI or
DEM. There were no age limits, and sensory or motor
deficits or other previous conditions were not reasons
for exclusion.
Procedure
All three screening tests were applied in a balanced
manner to all participants. Regardless of their test
results, all subsequently visited the Cognitive Behavioral
Neurology Unit (CBNU) of the Neurology Department
of Virgen de las Nieves University Hospital, Granada for
Figure 1 Phototest laminated sheet (version A).
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behavioral tests (Spanish adaptation of the NPI [29]),
functional tests (Barthel index [30], Lawton-Brody scale
[31], and Pfeffer’s FAQ [32]), and a detailed neuropsy-
chological examination (orientation, executive attention/
function [digit span, similarities, verbal fluency], verbal
memory [word list], language [abbreviated Boston nam-
ing test [33], comprehension of instructions, semantic
verbal fluency], visual-spatial functions [drawing, copy-
ing], calculation, and motor praxis). All of these tests
were conducted by researchers (SLA, MEG) blinded to
the PC results. None of the screening tests applied in
PC were administered in the CBNU evaluation. The
maximum time interval between assessments in the PC
center and CBNU was two weeks. Two expert neurolo-
gists in cognitive-behavioral neurology (CCP, BME) pro-
vided the gold standard diagnosis by consensus, based
on the CBNU evaluations and a detailed clinical assess-
ment; they classified subjects as: Non-CI (NoCI), CI
non-DEM (CInD) (criteria for mild cognitive impair-
ment of the Spanish Neurology Society Neurology and
Behavior Study Group [34]), or DEM (DSM-IVR criteria
[35]); any lack of consensus was resolved by the decision
of a third neurologist (RVC). All three experts were
blinded to the PC screening test results.
Statistical analysis
The effectiveness of the screening tests was assessed by
establishing the Sensitivity (Sn) and Specificity (Sp), diag-
nostic accuracy (DA = proportion of correct diagnoses),
and the kappa index of diagnostic concordance between
the screening test result, considering recommended cutoff
points, and the gold standard diagnosis [36]. Effectiveness
was calculated for DEM versus non-DEM (NoCI + CInD)
and for CI (DEM + CInD) versus NoCI. MMSE results for
DEM diagnosis were independently assessed following the
recommendations of Escribano-Aparicio et al [11] and the
NORMACODEM study [12], separately analyzing crude
scores and scores corrected by age and educational level.
Because there are no formal recommendations for CI
diagnosis, we applied the 26/27 cutoff point used in a
recent Spanish study [37]. MIS results were analyzed using
two different cutoff points for DEM, 3/4 [18] and
4/5 [19,20], and a single cutoff score of 4/5 for CI [18].
Phototest results were analyzed using a cutoff value of
26/27 for DEM and 28/29 for CI [22].
The cost analysis was based on the perspective of our
healthcare organization and took no account of the direct
costs of patients/carers, indirect or intangible costs, or of
the effects of diagnostic delay or false negatives (FNs). For
each test, we considered the minimum costs required to
reach the correct diagnosis for each condition. Hence, true
negatives (TNs) only incurred the cost of the PC consulta-
tion, whereas true positives (TPs) and false positives (FPs)
also incurred the costs of the CBNU study (professionals
[neurologist, neuropsychologist, nurse] and of the
minimum complementary tests recommended by the
Spanish Neurology Society [analytical, cranial CT-scan]),
and FNs required at least two PC consultations plus the
CBNU evaluation. The cost of the PC consultation was
taken from published rates and prices of the Andalusian
public healthcare system (Order of October 14 2005). The
costs of examinations in the CBNU were based on the
hospital’s financial accounts (Table 1). Calculations were
performed for each instrument on the minimum cost for
the whole sample, cost per correct diagnosis, and average
cost per subject.
SPSS version 15.0 (SPSS Inc., Chicago, IL) was used
for the data analyses, comparing qualitative variables
with the chi-square test or comparison of proportions
and quantitative variables with an ANOVA, applying the
Bonferroni test in post-hoc analysis. Effectiveness was
compared among instruments by using the McNemar
test for related samples, and costs were compared with
a t-test for related samples. P < 0.05 was considered sig-
nificant, and 95% confidence intervals were calculated
for all study variables.
Formal aspects
The study was approved by the Ethics and Research Com-
mittee of the Virgen de las Nieves University Hospital, and
written informed consent was obtained from all partici-
pants. The study design and report writing complied with
the STARD recommendations for diagnostic test studies
[38] and the recommendations of the Food and Drug
Administration for reporting diagnostic study results [36].
Results
Sample characteristics
The four PC centers in the study serve a population of
66,713 people, of whom around 16.7% are ≥65 years old
[39]. During the study period, PC physicians reported
suspicion of CI or DEM in 156 patients, due to subjec-
tive complaints in 70 cases (44.9%), third-party
Table 1 Minimum costs of diagnostic study
PC study 43.5€
Cost of PC physician consultation 43.5€
CBNU study 390.8€
Professionals (neurologist+neuropsychologist+nurse) 197.4€
Additional test (analysis+cranial CT scan) 193.4€
Costs per diagnoses
True Negative (PC study) 43.5€
True Positive (PC study + CBNU study) 434.4€
False Positive (PC study + CBNU study) 434.4€
False Negative ([PC study × 2] + CBNU study) 477.9€
PC: Primary Care; CBNU: Cognitive-Behavior Neurology Unit. CT: Computed
Tomography
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complaints in 76 (48.7%), and initial detection by the
physicians themselves in 10 (6.4%) cases. Out of the 156
patients enrolled in the study, 16 were excluded: 3 did
not give consent and 2 withdrew during the study; 4
were lost to the follow-up; and 5 were not fully evalu-
ated, due to sequelae of stroke or traumatic brain injury
and/or sensory impairment (amaurosis, anacusis), a pro-
tocol violation, and a recording error. Out of the 140
patients completing the study, 48 (34.3%) had DEM, 37
(26.4%) CInD, while 55 (39.3%) had neither CI nor
DEM (NoCI) (Figure 2).
Table 2 shows the socio-demographic characteristics
and screening test results of the participants, stratified by
cognitive diagnosis. Stratifications by “age” and “years of
education” were done for score corrections according to
NORMACODEM recommendations [12], and “educa-
tional level” categories were those used by Escribano-
Aparicio et al [11] to define different recommended cutoff
points.
The age of the study sample was 72.5 ± 11.3 yrs
(mean ± sd), and 72.1% were female; 20 (14.3%) were
illiterate and 52 (37.1%) had not completed primary
schooling. There was no significant gender difference
among diagnostic groups, but subjects with DEM were
older and had a lower educational level than those with
CInD or NoCI (p < 0.0001 for all comparisons). The
groups significantly differed in test results in the order
NoCI > CInD > DEM (p < 0.0001 for all comparisons)
with the exception of the corrected MMSE score, in
which the difference between NoCI and CInD groups
did not reach significance (p = 0.08).
Effectiveness and cost for DEM
For DEM (Table 3), the diagnostic concordance and
accuracy of MMSE were low (k = 0.30 [95% Confidence
Interval (95%CI), 0.16 to 0.44]; DA = 0.59 [95%CI, 0.46
to 0.73]) when NORMACODEM study criteria were
used [12]) and were not improved when scores were
corrected by age and educational level (k = 0.29 [95%CI,
0.15 to 0.43]; DA = 0.58 [95%CI, 0.46 to 0.72]). The
diagnostic concordance and accuracy were improved but
remained moderate (k = 0.50 [95%CI, 0.36 to 0.64];
DA = 0.74 [95%CI, 0.60 to 0.89]) when the recommen-
dations of Escribano-Aparicio et al [11] for populations
with low educational level were followed.
MIS could not be applied to 23 subjects (16.4% of the
sample), due to illiteracy (20) or minimum reading capa-
city associated with visual deficit (3). Among the 117
tested with MIS, a good diagnostic concordance (k = 0.63
[95%CI, 0.48 to 0.78]; DA = 0.83 [95%CI, 0.67 to 1.0]) was
obtained with a DEM cutoff score of 3/4, non-significantly
better than the concordance obtained with a cutoff of 4/5
(k = 0.54 [95%CI, 0.38 to 0.69]; DA = 0.78 [95%CI, 0.73 to
1.0]); the result was superior with either cutoff score to
any of the results obtained with MMSE. The diagnostic
concordance of Phototest was substantial (k = 0.70 [95%
CI, 0.57 to 0.83]; DA = 0.86 [95%CI, 0.72 to 1.00]), did not
significantly differ from that of MIS, and was significantly
superior to that of MMSE.
Sn and Sp values of Phototest (Sn = 0.81 [95%CI, 0.67
to 0.91], Sp = 0.89 [95%CI, 0.81 to 0.95]) did not signifi-
cantly differ from those of MIS with the cutoff point of
3/4 (Sn = 0.93 [95%CI, 0.78 to 0.99], c2 = 1.78, ns; Sp =
0.80 [95%CI, 0.71 to 0.88, c2 = 2.11, ns]) but differed
from those of MMSE (Sn = 0.96 [95%CI, 0.86 to 0.99],
c2 = 4.0, p < 0.05; Sp = 0.62 [95%CI, 0.51 to 0.72], c2 =
15.6, p < 0.001) (Table 4).
The mean cost of applying Phototest (208.2 ± 196.8 €)
did not significantly differ from that of the optimal MIS
approach (201.3 ± 193.4 €, t = 1.58, ns) but was signifi-
cantly lower versus the optimal MMSE approach (275.9
± 193.3 €, t = 4.2, p < 0.05), as depicted in Figure 3.
Effectiveness and cost in CI
For all instruments, the predictive validity was lower for
CI than for DEM (Table 5). No difference was found
between results obtained with MIS (k = 0.59 [95%CI,
0.45 to 0.74]; DA = 0.79 [95%CI, 0.64 to 0.97]) and
Phototest (k = 0.58 [95%CI, 0.45 to 0.74]; DA = 0.78
[95%CI, 0.64 to 0.95]), and both results were signifi-
cantly higher versus MMSE, using both crude scores
(k = 0.24 [95%CI, 0.06 to 0.43]; DA = 0.69 [95%CI, 0.55
to 0.84]) and scores corrected by age and educational
level (k = 0.27 [95%CI, 0.09 to 0.45]; DA = 0.69 [95%CI,
0.56 to 0.84]), which did not significantly differ between
them.
Figure 2 Flow diagram of study participants. PC: Primary Care;
CBNU: Cognitive Behavioral Neurology Unit; DEM: Dementia; CInD:
Cognitive impairment without dementia; NoCI: No cognitive
impairment.
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Sn and Sp values did not significantly differ between
MIS (S = 0.73 [95%CI, 0.61 to 0.94]; Sp = 0.87 [95%CI,
0.75 to 0.94]) and Phototest (S = 0.69 [95%CI, 0.58 to
0.79], c2 = 1.23, ns; Sp = 0.93 [95%CI, 0.82 to 0.98],
c2 = 0.31, ns) and were significantly lower for MMSE
(Table 6).
The mean cost of MMSE (398.7 ± 114.2 €) was sig-
nificantly higher than the cost of MIS (287.0 ± 197.4
€; t = 6.01, p < 0.0001) and Phototest (300.1 ± 195.6
€; t = 6.26, p < 0.0001), which did not significantly
differ between them (t = 0.47, ns), as depicted in
Figure 4.
Discussion
This study of CI and DEM screening test assessment in
an urban population with a low educational level shows
that MMSE is not very useful for DEM screening,
despite its widespread utilization. Its results were
improved by adopting the correction criteria proposed
by Escribano-Aparicio et al for populations with low
educational level, but they remained significantly inferior
to those obtained with Phototest and MIS.
Phototest, a short instrument that is rapid and easy to
use, showed a substantial diagnostic concordance for
DEM, correctly classifying 86% of the study sample,
Table 2 Socio-demographic characteristics and screening test results by diagnostic group
Total CI NoCI CInD DEM NoDEM
N° Subjects 140 85 55 37 48 92
N° females 101 (72.1) 60 (70.6) 41 (74.5) 23 (62.2) 37 (77.1) 64 (69.6)
Age in yrs* 72.5 ± 11.3 77.3 ± 7.6 64.9 ± 12.1 74.1 ± 7.3 79.6 ± 7.0 68.6 ± 11.3
≤ 50 yrs 7 (5.0) 0 (0) 7 (12.7%) 0 (0) 0 (0) 7 (7.6)
51-75 yrs 70 (50.0) 33 (37.5) 37 (67.3) 19 (51.4) 14 (27.5) 56 (60.9)
≥ 76 yrs 63 (45.0) 52 (61.2) 11 (20.0) 18 (48.6) 34 (70.8) 29 (31.2)
Educational Level#
Illiterates 20 (14.3) 19 (22.4) 1 (1.8) 3 (8.1) 16 (33.3) 4 (4.3)
Incomplete primary 52 (37.1) 35 (41.2) 17 (30.9) 16 (43.2) 19 (39.6) 33 (35.9)
Primary or more 68 (48.6) 31 (36.5) 37 (67.3) 18 (48.6) 13 (27.1) 55 (59.8)
Years of Education#
≤8 yrs 72 (51.4) 54 (63.5) 18 (32.7) 19 (51.4) 35 (72.9) 37 (40.2)
9-17 yrs 61 (43.6) 31 (36.5) 30 (54.5) 18 (48.6) 13 (21.3) 48 (52.2)
≥ 18 yrs 7 (5.0) 0 (0) 7 (12.7) 0 (0) 0 (0) 7 (7.6)
MMSE# 19.9 ± 5.7 17.2 ± 5.3 24.1 ± 3.1 21.8 ± 3.5 13.8 ± 3.6 23.2 ± 3.4
MMSEc@ 20.8 ± 5.2 18.5 ± 5.1 24.4 ± 2.9 22.8 ± 3.2 15.2 ± 3.7 23.7 ± 3.1












Phototest# 29.0 ± 7.6 25.4 ± 6.8 34.6 ± 5.1 30.5 ± 4.8 21.5 ± 5.5 32.9 ± 5.4
CI: cognitive impairment (CInD and DEM). NoCI: no cognitive impairment. CInD: cognitive impairment without dementia. DEM: dementia. NoDEM: no dementia
(NoCI and CInD).
MMSE: MiniMental State Examination. MMSEc: MMSE with corrected scores. MIS: Memory Impairment Screen.
The figures are n° of subjects (percentage) or mean ± sd; figures in square brackets = n° subjects able to take the MIS
* DEM > CInD > NoCI; DEM > NoDEM; CI > NoCI (p < 0.0001 all comparisons)
# NoCI > CInD > DEM; NoDEM > DEM; NoCI > CI (p < 0.0001 all comparisons)
@ (NoCI = CInD) > DEM; NoDEM > DEM; NoCI > CI; (NoCI vs CInD: ns; remaining comparisons, p < 0.0001)
Table 3 Effectiveness and cost of the screening tests for dementia
Test CoP Sn Sp DA k Total Cost (€) Cost/CD (€) Mean cost (€)
MMSE 24/25 1.00 (0.93-1.00) 0.38 (0.28-0.49) 0.59 (0.46-0.73) 0.30 (0.16-0.44) 47134.5 585.2 336.7 ± 169.9
MMSEc 24/25 1.00 (0.93-1.00) 0.37 (0.27-0.48) 0.58 (0.46-0.72) 0.29 (0.15-0.43) 47525.4 570.6 339.5 ± 168.2
MMSE * 0.96 (0.86-0.99) 0.62 (0.51-0.72) 0.74 (0.60-0.89) 0.50 (0.36-0.64) 38621.7 377.9 275.9 ± 193.3
MIS# 3/4 0.93 (0.78-0.99) 0.80 (0.71-0.88) 0.83 (0.67-1.00) 0.63 (0.48-0.78) 23548.6 242.5 201.3 ± 193.4
MIS# 4/5 0.96 (0.78-1.00) 0.71 (0.61-0.80) 0.78 (0.73-1.00) 0.54 (0.38-0.69) 26632.5 295.6 227.6 ± 196.4
Phototest 26/27 0.81 (0.67-0.91) 0.89 (0.81-0.95) 0.86 (0.72-1.00) 0.70 (0.57-0.83) 29153.7 242.1 208.2 ± 196.8
CoP: Cutoff point; Sn: sensitivity; Sp: specificity; DA: diagnostic accuracy (proportion of correct diagnoses); k: kappa index. Cost/CD: total cost divided by n° correct
diagnoses. Mean cost: mean ± sd. In brackets, 95% confidence interval.
MMSE: MiniMental State Examination. MMSEc: MMSE with corrected scores. MIS: Memory Impairment Screen
*Cutoff points: 17/18: illiterates; 20/21: literate but did not complete primary schooling; 23/24: primary schooling or higher
#Results for the 117 subjects who completed the MIS
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similar to the percentage obtained using MIS with a cut-
off score of 3/4. However, unlike Phototest, MIS
requires reading ability and could not be applied to an
appreciable proportion of our study population (16.4%).
Although all instruments were significantly less useful
for CI than for DEM, Phototest correctly classified 78%
of patients as CI or non-CI, a similar percentage to that
obtained with MIS. MMSE was the least useful instru-
ment to screen for CI.
To our knowledge, this is the first study of CI and
DEM screening tests to evaluate the costs associated with
utilization of the test instruments. MMSE was associated
with significantly higher costs for both DEM and CI, with
no significant difference in the costs of Phototest and
MIS. Considering the whole study sample, there was a
difference between Phototest and the optimal MMSE
approach of 13,807.3 € for CI screening and 9,468 € for
DEM. Extrapolation of this difference to the whole popu-
lation served by the unit (i.e., around 500,000 versus
66,713 subjects) indicates that the use of Phototest
instead of MMSE would yield savings of around 70,000-
135,000 € per year at present prices. Although the pre-
sent study is not strictly a cost-effectiveness analysis [40],
it can be concluded from our data on effectiveness and
costs that Phototest is the best option for CI and DEM
screening, offering higher effectiveness at lower cost in
comparison to MMSE and allowing the assessments
of all subjects, unlike MIS. This is valuable information
for the efficient allocation of resources when these are
limited [41].
The fact that MIS cannot be used with illiterates may
appear irrelevant given the tendency to an improvement
in educational level and the aim of universal literacy
[42]. However, illiteracy remains a worldwide problem,
with over 750 million illiterates in 2010 [43], and it is
not limited to underdeveloped countries, affecting 3% of
adults in the USA. i.e., around 7 million people [44].
Account must also be taken of the increasing frequency
of “relative illiteracy” derived from emigration and tour-
ism [45], resulting in large numbers of people who are
literate in their mother tongue and can express them-
selves verbally in the language of their country of resi-
dence but have inadequate reading skills in the new
language for assessment with instruments that require
this ability. This situation is considered to affect 2% of
adults in the USA, i.e., around four million people [44].
In short, instruments that do not require reading skills
remain necessary to assess the whole population.
The main strengths of this study are the prospective,
consecutive, and systematic nature of the recruitment,
the long study period, the virtual absence of exclusion
Table 4 Comparison of the effectiveness of screening tests for dementia, considering the most favorable MMSE and
MIS approaches
DEM NoDEM
Test Phototest ≤26 Phototest ≥27 Total Phototest ≤26 Phototest ≥27 Total
MMSE* + 38 8 46 4 31 35
MMSE* - 1 1 2 6 51 57
Total 39 9 48 10 82 92
c2 = 4; p < 0.05 c2 = 15.6, p < 0.001
MIS ≤3# 21 7 28 5 12 17
MIS ≥4# 2 0 2 5 65 70
Total# 23 7 30 10 77 87
c2 = 1.78; n.s. c2 = 2.11; n.s.
DEM: dementia; NoDEM: No dementia. MMSE: MiniMental State Examination. MIS: Memory Impairment Screen
Values are the n° of subjects
*Cutoff points: 17/18: illiterates; 20/21: literate but did not complete primary schooling; 23/24: primary schooling or higher
#Results for the 117 subjects who completed the MIS
Figure 3 Cost per correct diagnosis for dementia . MMSE:
MiniMental State Examination. MMSEc: MMSE with corrected scores.
MIS: Memory Impairment Screen. CD: correct diagnoses. *Cutoff
points: 17/18: illiterates; 20/21: literate but did not complete primary
schooling; 23/24: primary schooling or higher #Results for the 117
subjects who completed the MIS
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criteria, and the low loss index. As a result, the study
sample is a faithful reflection of the diagnostic chal-
lenges faced under routine clinical conditions in this
field of care, making the study naturalistic and prag-
matic and allowing robust results that can be considered
effectiveness rather than efficacy estimators. Further-
more, the main biases in diagnostic test assessment stu-
dies [46] were avoided by the fact that all subjects
underwent all screening tests, all received a gold stan-
dard diagnosis, regardless of their screening test results,
and the screening test results and gold standard diag-
noses were all evaluated in a blinded and independent
manner.
One study limitation is that it may not be possible to
extrapolate the results, especially those for the MMSE,
to more educated populations. The low specificity of
MMSE was undoubtedly due to the low educational
level of our sample. This shortcoming is avoided by the
Phototest, whose results are not affected by educational
level [24]. The present results for the overall usefulness
of the Phototest are virtually identical to those obtained
in a previous multicenter study (FOTOTRANS study)
conducted under routine clinical conditions, which used
the same cutoff points and found a sensitivity of 0.88
and specificity of 0.87 for DEM, and sensitivity of 0.68
and specificity of 0.89 for CI [25,26]. In the FOTO-
TRANS study, the diagnostic accuracy of the Phototest
was similar to that of the Eurotest [47], another valid
and reliable cognitive test applicable to illiterates and
developed by our group [48,49]. However, the Eurotest
requires 7 minutes to complete and is therefore less use-
ful in PC, in which time constraints are crucial [50].
The present results found for MIS with a cutoff point
of 3/4 are also very similar to the findings by Perez-
Martinez et al in a prospective clinical sample with low
educational level (Sn = 0.93, Sp = 0.73) [18] but differ
from those reported in two other studies (Sn = 0.74, Sp =
0.96, and Sn = 0.84, Sp = 0.94, respectively) [19,20]. In
these two studies, the specificity was higher than the sen-
sitivity, possibly because of the different cutoff point used
(4/5), the cross-sectional design of the studies, and the
higher overall educational level of the samples, which did
not include subjects with CI, facilitating the discrimina-
tion between DEM and non-DEM and therefore overesti-
mating the diagnostic usefulness.
Although our sample size may appear to be a limita-
tion, it allowed the precise estimation of proportions
(6-8%). Furthermore, the use of a one-year recruitment
period allowed seasonal biases to be avoided and
ensured greater sample representativeness.
Table 5 Effectiveness and cost of screening tests for cognitive impairment
Test CoP Sn Sp DA k Total Cost (€) Cost/CD Mean cost (€)
MMSE 26/27 0.96 (0.90-0.99) 0.24 (0.13-0.37) 0.69 (0.55-0.84) 0.24 (0.06-0.43) 55821.3 577.9 398.7 ± 114.2
MMSEc 26/27 0.96 (0.90-0.99) 0.27 (0.16-0.41) 0.69 (0.56-0.84) 0.27 (0.09-0.45) 55582.8 575.4 393.4 ± 121.8
MIS# 4/5 0.73 (0.61-0.84) 0.87 (0.75-0.94) 0.79 (0.64-0.97) 0.59 (0.45-0.74) 33582.9 363.3 287.0 ± 197.4
Phototest 28/29 0.69 (0.58-0.79) 0.93 (0.82-0.98) 0.78 (0.64-0.95) 0.58 (0.45-0.74) 42014.0 379.8 300.1 ± 195.6
CoP: Cutoff point; Sn: sensitivity; Sp: specificity; DA: diagnostic accuracy (proportion correct diagnosis); k: kappa index. Cost/CD: total cost divided by n° correct
diagnoses. Mean cost: mean ± sd. In brackets, 95% confidence interval.
MMSE: MiniMental State Examination. MMSEc: MMSE with corrected scores. MIS: Memory Impairment Screen
#Results for the 117 subjects who completed the MIS
Table 6 Comparison of the effectiveness of screening tests for cognitive impairment (most favorable alternatives for
MMSE and MIS)
CI NoCI
Test Phototest≤28 Phototest≥29 Total Phototest≤28 Phototest≥29 Total
MMSEc ≤26 58 24 82 4 36 40
MMSEc ≥27 1 2 3 0 15 15
Total 59 26 85 4 51 55
c2 = 19.36; p < 0.001 c2 = 32.11; p < 0.001
MIS ≤4# 38 9 47 0 7 7
MIS ≥5# 4 13 17 4 42 46
Total# 42 22 64 4 49 53
c2 = 1.23; ns c2 = 0.31; ns
CI: cognitive impairment; NoCI: No cognitive impairment. MMSE: MiniMental State Examination. MMSEc: MMSE with corrected scores. MIS: Memory Impairment
Screen.
Values are the n° of subjects
#Results referred to the 117 subjects who completed the MIS
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Finally, our economic analysis was simplistic and basic
and cannot strictly be considered a cost-effectiveness
study [40]. Nevertheless, our approach to minimum
costing was real and pragmatic and allowed differential
costs to be established among the different screening
test options. Our data should facilitate decision-making
to improve the assignment of resources. In this regard,
our results suggest that MMSE is not suitable for use in
our setting and that MIS and Phototest are preferable
due to their lower cost and higher effectiveness. The
Phototest can be especially recommended because,
unlike the MIS, it can be completed by all subjects,
including the illiterate.
Conclusions
In this prospective phase III study of diagnostic test
assessment in a population with low educational level, we
assessed, in a blinded and independent manner, the effec-
tiveness and cost of CI and DEM screening using three
tests: MMSE and MIS, the most widely used tests in PC,
and Phototest, a short, easily applied test that can be
used in illiterates and whose results are not influenced by
educational level. MMSE proved to be the least effective
and most expensive option, with a low diagnostic useful-
ness. The effectiveness of MIS and Phototest was sub-
stantially higher than that of MMSE, and their associated
costs were lower. However, MIS could not be applied to
illiterates, whereas Phototest could be used with the
whole sample. The application in PC of Phototest rather
than MMSE to screen for CI and DEM in our setting
would improve the effectiveness of the screening, reduce
the workload of healthcare professionals, and lower the
associated costs, permitting a better distribution of
resources.
Additional material
Additional file 1: Phototest. Form with instructions for the application
and correction of the Phototest.
Additional file 2: Phototest laminated sheet (version B). Laminated
sheet with stimulus images in the version for English-speaking countries.
Acknowledgements
The study was funded by the Agencia de Evaluacion de Tecnologias
Sanitarias, Instituto de Salud Carlos III (Expdte PI06/90034). The funding
source had no role in the study design, data collection, analysis, or
interpretation or in the writing of the report.
The authors are grateful to F. Padilla Ruiz, S. Cárdenas Viedma, M. Melguizo
Jimenez, and M. Alonso Rodenas, directors of the participating centers, and
all primary care professionals involved in the study. The authors also thank
R. de la Vega Cotarelo for reviewing the manuscript and contributing
invaluable advice and R. Davies for editorial assistance, including the
translation.
Author details
1Cognitive Behavioral Neurology Unit, Service of Neurology, Virgen de las
Nieves University Hospital, Carretera de Jaen s/n, 18013 - Granada, Spain.
2FIDYAN Neurocenter, Mozart s/n, Edf. Zafiro, 18004 - Granada, Spain.
3Service of Neurology, La Mancha Center Hospital Complex, Alcazar de San
Juan, 13600 - Ciudad Real, Spain. 4Departament of Psychobiology, School of
Psychology, University of Jaen, Campus Las Lagunillas s/n, 23071 - Jaen,
Spain. 5Management Control Section, Virgen de las Nieves University
Hospital, Carretera de Jaen s/n, 18013 - Granada, Spain.
Authors’ contributions
CCP formulated the study design, led the data collection, carried out the
analyses, interpreted the results, and wrote the first draft of the manuscript.
EHT and JLNE discussed the study design, calculated costs, assisted with the
data analyses and results interpretation. BEM, SLA, MEG, CSZ, and RVC
discussed the study design, collected data and commented on results. All
authors read and approved the final manuscript.
Competing interests
C. Carnero-Pardo is the creator of the Phototest and Eurotest.
Received: 24 March 2011 Accepted: 29 July 2011
Published: 29 July 2011
References
1. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL,
DeKosky ST: Practice parameter: early detection of dementia: mild
cognitive impairment (an evidence-based review). Report of the Quality
Standards Subcommittee of the American Academy of Neurology.
Neurology 2001, 56(9):1133-1142.
2. Boustani M, Peterson B, Hanson L, Harris R, Lohr KN: Screening for
dementia in primary care: a summary of the evidence for the U.S.
Preventive Services Task Force. Annals of internal medicine 2003,
138(11):927-937.
3. National Collaboration Centre for Mental Health: Dementia. A NICE-SCIE
Guideline on supporting people with dementia and their carers in
health and social care. National Clinical Practice Guideline Number 42.
The British Psychological Society & The Royal College of Psychiatrists; 2007.
4. Carnero Pardo C: Test de screening en demencia. In Neurología
conductual: fundamentos teoricos y practicos. Edited by: Manubens Bertran J,
Berthier Torres M, Barquero Jiménez S. Barcelona: Pulso Ediciones SL; 2002.
5. Ismail Z, Rajji TK, Shulman KI: Brief cognitive screening instruments: an
update. Int J Geriatr Psychiatry 2010, 25(2):111-120.
6. Hensel A, Angermeyer MC, Riedel-Heller SG: Measuring cognitive change
in older adults: reliable change indices for the Mini-Mental State
Examination. J Neurol Neurosurg Psychiatry 2007, 78(12):1298-1303.
7. Mitchell AJ: A meta-analysis of the accuracy of the mini-mental state
examination in the detection of dementia and mild cognitive
impairment. J Psychiatr Res 2009, 43(4):411-431.
Figure 4 Cost per correct diagnosis for cognitive impairment.
MMSE: MiniMental State Examination. MMSEc: MMSE with corrected
scores. MIS: Memory Impairment Screen. CD: correct diagnosis.
*Cutoff points: 17/18: illiterates; 20/21: literate but did not complete
primary schooling; 23/24: primary schooling or higher. #Results for
the 117 subjects who completed the MIS
Carnero-Pardo et al. BMC Neurology 2011, 11:92
http://www.biomedcentral.com/1471-2377/11/92
Page 8 of 9
8. Rosselli D, Ardila A, Pradilla G, Morillo L, Bautista L, Rey O, Camacho M: [The
Mini-Mental State Examination as a selected diagnostic test for
dementia: a Colombian population study. GENECO]. Revista de neurologia
2000, 30(5):428-432.
9. Scazufca M, Almeida OP, Vallada HP, Tasse WA, Menezes PR: Limitations of
the Mini-Mental State Examination for screening dementia in a
community with low socioeconomic status: results from the Sao Paulo
Ageing & Health Study. Eur Arch Psychiatry Clin Neurosci 2009, 259(1):8-15.
10. Gimenez-Roldan S, Novillo MJ, Navarro E, Dobato JL, Gimenez-Zuccarelli M:
[Mini-mental state examination: proposal of protocol to be used]. Revista
de neurologia 1997, 25(140):576-583.
11. Escribano-Aparicio MV, Perez-Dively M, Garcia-Garcia FJ, Perez-Martin A,
Romero L, Ferrer F, Martin-Correa E, Sanchez-Ayala MI: Validacion del
MMSE de Folstein en una poblacion española de bajo nivel educativo.
Rev Esp Geriatr Gerontol 1999, 34:319-326.
12. Blesa R, Pujol M, Aguilar M, Santacruz P, Bertran-Serra I, Hernandez G,
Sol JM, Pena-Casanova J: Clinical validity of the ‘mini-mental state’ for
Spanish speaking communities. Neuropsychologia 2001, 39(11):1150-1157.
13. Brodaty H, Low LF, Gibson L, Burns K: What is the best dementia
screening instrument for general practitioners to use? Am J Geriatr
Psychiatry 2006, 14(5):391-400.
14. Milne A, Culverwell A, Guss R, Tuppen J, Whelton R: Screening for
dementia in primary care: a review of the use, efficacy and quality of
measures. Int Psychogeriatr 2008, 20(5):911-926.
15. Brodaty H, Pond D, Kemp NM, Luscombe G, Harding L, Berman K,
Huppert FA: The GPCOG: a new screening test for dementia designed
for general practice. J Am Geriatr Soc 2002, 50(3):530-534.
16. Borson S, Scanlan J, Brush M, Vitaliano P, Dokmak A: The mini-cog: a
cognitive ‘vital signs’ measure for dementia screening in multi-lingual
elderly. Int J Geriatr Psychiatry 2000, 15(11):1021-1027.
17. Buschke H, Kuslansky G, Katz M, Stewart WF, Sliwinski MJ, Eckholdt HM,
Lipton RB: Screening for dementia with the memory impairment screen.
Neurology 1999, 52(2):231-238.
18. Perez-Martinez DA, Baztan JJ, Gonzalez-Becerra M, Socorro A: [Evaluation of
the diagnostic value of a Spanish adaptation of the Buschke Memory
Impairment Screen in the detection of dementia and cognitive
impairment]. Revista de neurologia 2005, 40(11):644-648.
19. Bohm P, Pena-Casanova J, Gramunt N, Manero RM, Terron C, Quinones-
Ubeda S: [Spanish version of the Memory Impairment Screen (MIS):
normative data and discriminant validity]. Neurologia 2005, 20(8):402-411.
20. Barrero-Hernandez FJ, Vives-Montero F, Morales-Gordo B: [Evaluation of the
Spanish version of the Memory Impairment Screen]. Revista de neurologia
2006, 43(1):15-19.
21. Carnero-Pardo C, Montoro-Rios MT: [The photo test]. Rev Neurol 2004,
39(9):801-806.
22. Carnero-Pardo C, Saez-Zea C, Montiel Navarro L, Del Saz P, Feria Vilar I,
Pérez Navarro MJ, Ruiz Gimenez J, Vilchez Carrillo R, Montoro Rios MT:
[Diagnostic accuracy of the Phototest for cognitive impairment and
dementia]. Neurologia 2007, 22(10):860-869.
23. Saez-Zea C, Carnero-Pardo C, Gurpegui M: [Names of persons: a verbal
fluency test without socioeducational influences]. Neurologia 2008,
23(6):356-360.
24. Carnero-Pardo C, Saez-Zea C, Montiel-Navarro L, Feria-Vilar I, Gurpegui M:
Normative and reliability study of fototest. Neurologia 2011, 26(1):20-25.
25. Carnero-Pardo C, Saez-Zea C, de la Vega Cotarelo R, Gurpegui M, in behalf
of FOTOTRANS group: Estudio Fototrans. Estudio multicentrico sobre la
validez del Fototest en condiciones de practica clinica. Neurologia .
26. Saez-Zea C: Utilidad diagnostica, fiabilidad y validez del Fototest en la
deteccion de deterioro cognitivo y demencia. Doctoral thesis. Granada
University, Neuroscience Institute “Federico Olóriz”; 2009.
27. Sackett DL, Haynes RB: The architecture of diagnostic research. BMJ 2002,
324(7336):539-541.
28. Bossuyt PM, Irwig L, Craig J, Glasziou P: Comparative accuracy: assessing new
tests against existing diagnostic pathways. BMJ 2006, 332(7549):1089-1092.
29. Boada M, Cejudo JC, Tarraga L, Lopez OL, Kaufer D: [Neuropsychiatric
inventory questionnaire (NPI-Q): Spanish validation of an abridged form
of the Neuropsychiatric Inventory (NPI)]. Neurologia 2002, 17(6):317-323.
30. Mahoney FI, Barthel DW: Functional Evaluation: The Barthel Index. Md
State Med J 1965, 14:61-65.
31. Lawton MP, Brody EM: Assessment of older people: self-maintaining and
instrumental activities of daily living. Gerontologist 1969, 9(3):179-186.
32. Pfeffer RI, Kurosaki TT, Harrah CH Jr, Chance JM, Filos S: Measurement of
functional activities in older adults in the community. J Gerontol 1982,
37(3):323-329.
33. Calero MD, Arnedo ML, Navarro E, Ruiz-Pedrosa M, Carnero C: Usefulness
of a 15-item version of the Boston Naming Test in neuropsychological
assessment of low-educational elders with dementia. J Gerontol B Psychol
Sci Soc Sci 2002, 57(2):P187-191.
34. Robles A, Del Ser T, Alom J, Pena-Casanova J: [Proposal of criteria for
clinical diagnosis of mild cognitive impairment, dementia and
Alzheimer’s disease]. Neurologia 2002, 17(1):17-32.
35. American Psychiatric Association: Diagnostic and Statistical Manual of
Mental Disorders (4th ed., text revision) DSM-IV-TR. Washington DC:
American Psychiatric Association; 2000.
36. Statistical guidance on reporting results from studies evaluating
diagnostic test. U. S. Department of Health and Human Services, Food
and Drug Administration, Center for Devices and Radiological Health,
Diagnostic Devices Branch, Division of Bioestatistic, Office of Surveillance
and Biometrics; 2003.
37. Rami L, Bosch B, Valls-Pedret C, Caprile C, Sanchez-Valle Diaz R, Molinuevo JL:
[Discriminatory validity and association of the mini-mental test (MMSE)
and the memory alteration test (M@T) with a neuropsychological battery
in patients with amnestic mild cognitive impairment and Alzheimer’s
disease]. Revista de neurologia 2009, 49(4):169-174.
38. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM,
Lijmer JG, Moher D, Rennie D, de Vet HC: Towards complete and accurate
reporting of studies of diagnostic accuracy: the STARD initiative. BMJ
2003, 326(7379):41-44.
39. Censo de Poblacion. Instituto de Estadistica de Andalucia: Consejeria de
Economia, Innovacion y Ciencia; 2001.
40. Gold MR, Siegel JE, Russell LB, Weinstein MC: Cost-effectiveness in health
and medicine. New York: Oxford University Press; 1996.
41. Oliver A, Healey A, Donaldson C: Choosing the method to match the
perspective: economic assessment and its implications for health-
services efficiency. The Lancet 2002, 359(9319):1771-1774.
42. EPT report team: The Dakar framework for action. Education for all:
meeting our collective commitments. UNESCO; 2000.
43. EPT monitoring report team: Report 2010. Reaching the marginalized.
Education for all global monitoring report Paris: UNESCO; 2010.
44. Kutner M, Greenberg E, Jin Y, Boyle B, Hsu Y, Dunleavy E: Literacy in Every
Life: Results from the 2003 National Assessment of adult literacy (NCES
2007-480). U.S. Department of Education. Washington, DC: National Center
for Education Statistic; 2007.
45. Carnero Pardo C: Analfabetismo, bajo nivel educativo y muestras
normativas para pruebas neuropsicologicas. Neurologia 2005, 20(1):49.
46. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J: The development
of QUADAS: a tool for the quality assessment of studies of diagnostic
accuracy included in systematic reviews. BMC Med Res Methodol 2003,
3:25.
47. Carnero-Pardo C, Montoro-Rios MT: [Preliminary evaluation of a new
screening test for dementia (Eurotest)]. Revista de neurologia 2004,
38(3):201-209.
48. Carnero-Pardo C, Gurpegui M, Sanchez-Cantalejo E, Frank A, Mola S,
Barquero MS, Montoro-Rios MT: Diagnostic accuracy of the Eurotest for
dementia: a naturalistic, multicenter phase II study. BMC neurology 2006,
6:15.
49. Carnero-Pardo C, Gurpegui M, Sanchez-Cantalejo E, Gomez-Camello A,
Guardado-Santervas P, Montoro- Rios MT: [Reliability assessment of the
EUROTEST]. Neurologia 2007, 22(3):153-158.
50. Deveugele M, Derese A, van den Brink-Muinen A, Bensing J, De
Maeseneer J: Consultation length in general practice: cross sectional
study in six European countries. BMJ 2002, 325(7362):472.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2377/11/92/prepub
doi:10.1186/1471-2377-11-92
Cite this article as: Carnero-Pardo et al.: Effectiveness and costs of
phototest in dementia and cognitive impairment screening. BMC
Neurology 2011 11:92.
Carnero-Pardo et al. BMC Neurology 2011, 11:92
http://www.biomedcentral.com/1471-2377/11/92
Page 9 of 9
